Hld-0117

Phase 1

Johnson & Johnson

Hld-0117 is one of 46 therapeutic programs targeting Metastatic Breast Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Metastatic Breast CancerRecruiting

Metastatic Breast CancerPhase 1

Recruiting

Competition

Competitive Landscape

46 competitors in Metastatic Breast Cancer

#DrugCompanyPhaseTrials

Kisqali

Novartis

Approved

6 2

Femara

Novartis

Approved

3 3

Nolvadex

AstraZeneca

Approved

2 4

Faslodex

FFresenius Kabi USA, LLC

Approved

8 5

Arimidex

IIstituto Clinico Humanitas

Approved

3 6

Zoladex

TTerSera Therapeutics LLC

Approved

1 7

Herceptin

Roche

Phase 3

5 8

Abraxane

Bristol-Myers Squibb

Phase 3

3 9

Taxol

Teva

Phase 3

3 10

Aromasin

Pfizer

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

Phase 1Recruiting

Metastatic Breast Cancer

NCT07524855

Clinical

Trials by Indication[1]

Metastatic Breast Cancer1 trial

A Phase 1 Study of JNJ-101684362 (HLD-0117) in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer (MBC)

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT07524855·170 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Hld-0117. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Hld-0117. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: Johnson & Johnson

Hld-0117

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2030

Trials by Indication[1]

Metastatic Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News